Key facts
- Notable investors include Suzhou Guofa Venture Capital, Hony Capital, Med-Fine Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tianyikang Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Tianyikang Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tianyikang Pharmaceutical
Provider of cell immunotherapy research and development focused on advancing medical research and cell technology applications to develop next-generation immunotherapy products. The company conducts cell technology development, medical research, immunotherapy product development and related laboratory research activities, serving healthcare institutions and the biotechnology sector by enabling the advancement of innovative treatment approaches for cancer and other serious diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Tianyikang Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tianyikang Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tianyikang Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.